FORWARD LOOKING STATEMENT

Similar documents
Forward-looking Statement Disclaimer

Clinical Policy: EpiFix Wound Treatment

Ampion TM. Management Presentation 2018

Use of Placental Tissue for Orthopedic Injuries: Potentials and Pitfalls. Daniel Kuebler, PhD Franciscan University of Steubenville

HUMAN AMNIOTIC MEMBRANE GRAFTS TO ENHANCE HEALING. Frank Burrows, MBA, EMT David Mason, MD

Charles Zelen, DPM Attila Poka, MD James Andrews, MD

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

FEP Medical Policy Manual

Committed to Transforming the Treatment Paradigm for Migraine Prevention

PATENCY-1 Top-Line Results

Ampion TM. Management Presentation January 2018

WOUND CARE UPDATE. -Commonly Used Skin Substitute Products For Wound. -Total Contact Casting. Jack W. Hutter DPM, FACFAS, C. ped.

medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

HTX-011 Postoperative Pain Program Topline Results from Phase 2b Studies. June 21, 2018

FEP Medical Policy Manual

Committed to Transforming the Treatment Paradigm for Migraine Prevention

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

Diagnostics for the early detection and prevention of colon cancer. Leerink Swann Global Health Care Conference February 2015

NeoCart Phase 3 Clinical Trial Results Call

Medical Coverage Policy Amniotic Membrane and Amniotic Fluid EFFECTIVE DATE: POLICY LAST UPDATED:

Asterias Biotherapeutics NYSE American: AST

Cell Therapy. Cytori Corporate Presentation January 2012

UBS Global Healthcare Conference May 19, 2014

WHS Abstract selected for the podium presentation and WHS Industrial Research & Development Poster

Granulox Update on evidence and science

34 th Annual J.P. Morgan Healthcare Conference

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

WPS Medicare Policy Primer

Corporate Presentation Fourth Quarter 2017

37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019

Genomic Health. Kim Popovits, Chairman, CEO and President

January 2017 Investor Presentation. confidently live life with ease

The Georgetown Team Approach to Diabetic Limb Salvage: 2013

Forward Looking Statements and Further Information

Apligraf A Reimbursement Case Study Antonio S. Montecalvo, CPA Director of Customer Support Services ISCT San Diego - May 5th, 2009

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights

ORTHOPEDIC SPECIALISTS STEM CELLS FOR THE TREATMENT OF PAIN DISCOVERING A NEW PATH TO WELLNESS

First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International

AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018

Original Research. and increased bacterial infiltration resulting in a disordered and uncoordinated

November 2, Q Financial Results

NASDAQ: ZGNX. Company Presentation. October 2017

Cowen Investor Conference March confidently live life with ease

BioCryst Pharmaceuticals

Company Overview. Dr. Neal Walker President and CEO. September Copyright 2016 Aclaris Therapeutics. All rights reserved.

Diagnostics for the early detection and prevention of colorectal cancer.

Jefferies 2015 Global Healthcare Conference June 1, 2015

C Y T O R I. Personalized Cell Therapy A TRUSTED LEADER IN CELL THERAPY NASDAQ: CYTX

Bank of America Merrill Lynch 2016 Health Care Conference

Building a Stroke Portfolio. June 28, 2018

Solutions For The Aging Spine

Dynavax Corporate Presentation

Mainstay Medical Announces Headline Results from ReActiv8-B Clinical Study

The management of chronic

DermaSpan Acellular Dermal Matrix. Reinforcement of Ruptured Posterior Tibial Tendon Repair. Surgical Protocol by Charles Zelen, DPM, FACFAS

J.P. Morgan Healthcare Conference

SAKURA 3 Open-Label Phase 3 Safety Study with DaxibotulinumtoxinA for Injection (RT002) for the Treatment of Moderate to Severe Glabellar Lines

MANIFEST Phase 2 Enhancement / Expansion

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

Building a Premier Oncology Biotech

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

Annual Stockholder Meeting May 30, confidently live life with ease

Amniotic Membrane Tissue Allografts: Arthrofibrosis & TKR

Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018

STUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017

Building a Fully Integrated Biopharmaceutical Company. June 2014

Company Presentation March Nasdaq: MDWD

Jefferies Healthcare Conference June 6, 2018

February 23, Q4 and Year-End 2016 Financial Results

PRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March

MARINE Study Results

Forward-Looking Statements

The New England Journal of Medicine. A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

August 7, Q Financial Results

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT

Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011

Innovation In Ophthalmology

Building a Premier Oncology Biotech

Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss

Spectrum Pharmaceuticals

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

Corporate Presentation. August 2016

PLEO-CMT Top-line Results. Presentation October 16, 2018

Corporate Presentation. First Quarter 2018

Company Update. August 8, 2018

PROMISE 2 Top-Line Data Results January 8, 2018

Innovation In Ophthalmics

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Clinical Review Criteria

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

January 30, 2018 Dow Wilson President and Chief Executive Officer

Agreement to Acquire Spinal Kinetics, Inc. March 15, 2018

Corporate Presentation

Transcription:

June 2018

FORWARD LOOKING STATEMENT This presentation includes forward looking statements regarding: future incremental insurance coverage; future size of sales force; future approved indications for use of our products; future products and markets, and the expected size of such markets; and the expected timing of clinical studies, BLA filings and product launches. Other forward looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management s current beliefs and expectations. These forward looking statements are subject to significant risks and uncertainties, and we caution investors against placing undue reliance on such statements. Actual results may differ materially. The Company provides additional information concerning factors that could cause actual results to differ materially in the Risk Factors section of the Company s most recent annual report or quarterly report filed with the Securities and Exchange Commission. Any forward looking statements speak only as of the date hereof, and the Company assumes no obligation to update any forward looking statement. 2

COMPANY HIGHLIGHTS Leading Developer and Marketer of Regenerative and Therapeutic Biologics based on a Placental Technology Platform Addressing Multi Billion Dollar Market Opportunities in Wound Care, Surgical and Musculoskeletal Pain Core Wound Care Business with Late Stage Therapeutics Pipeline GMP Compliant and US Pharmacopeia (USP) Monograph for Strength, Quality, and Purity of MiMedx Allografts Proven Safety Profile; More than 1 Million Allograft Units Shipped Over 100* Issued and Allowed Patents Capital Allocation for Shareholder Value Creation Investing for Growth *owned and licensed 3

AMNIOTIC MEMBRANE: MASTER REGULATOR OF BIOLOGY Hundreds of Growth Factors and Peptides Associated with Tissue Generation 1 Immunologically Privileged 2 Highly Biocompatible Key Actions: Modulates (reset) Inflammation 3 Regulates Cell Migration, Proliferation, and Metabolism Promotes Angiogenesis and Stem Cell Recruitment Reduces Scar Tissue Formation 3 Offers Barrier Properties 4 Enhances Healing 5 1 Tao H, Fan H. Eur Spine J. 2009 Aug; 18(8):1202 12. 2 Tseng SC, Li DQ, Ma X. J Cell Physiol. 1999 Jun;179(3):325 35. 3 Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Cornea. 2000 May;19(3):348 52. 4 Koob TJ, Rennert R, Zabek N, et al. Int Wound J. 2013 Oct;10(5):493 500. 5 Zelen CM, Serena TE, Denozière G, Fetterolf DE. Int Wound J. 2013 Oct;10(5):502 7. 4

INNOVATIVE TECHNOLOGY PLATFORMS dhacm Core Technology Equivalent EpiFix (sheet dhacm) Flagship Amnion/ Chorion grafts used as a barrier membrane for proven, enhanced healing power Smaller wounds Various surgical applications AmnioFix (injectable dhacm) Same dhacm in micronized, injectable formulation Smaller wounds Various surgical applications Tendonitis and Osteoarthritis* EpiCord (Umbilical Cord) Provides a protective environment for the healing process Smaller wounds requiring a graft that can hold a stitch Longer site coverage timeframe When a thicker graft is needed for coverage/ padding AmnioFill (placental tissue based product) Contains same Growth Factors found in PURION Processed tissues Replaces or supplements damaged or inadequate integumental tissue to provide a scaffold for cells to attach and proliferate Larger and uneven surface areas >25cm 2 NOT injectable 5 * Conducting IND/BLA program for Plantar Fasciitis, Achilles Tendonitis and Osteoarthritic Knee Pain

TARGETED WELL DEFINED GROWTH STRATEGY Gain Market Share Educate Market; Expand Scientific/Clinical Body of Evidence Grow Direct Salesforce (440+ and growing) Increase Insured Lives (new VLU coverage) Expand Market Opportunity Increase Use with Current Customers Broaden Physician Practices, IDNs and Clinics Target High Value Surgical Procedures (4.3M orthopedic, GYN, Plastics, Colorectal and Urology procedures annually) Further Penetrate GPO and IDN contracts (VAC approvals) International Expansion, Product Line Expansion, New Uses and Indications 6

CHRONIC WOUND MARKET IS UNDERPENETRATED 1.4M Chronic DFU/VLU Wounds $3B Market Opportunity 2017 U.S. Market Facts Skin/Dermal Substitutes is Largest Segment of Chronic Wound Care Market Placenta Derived/ Amniotic Tissue Products Major Growth Driver 3M are nonhealing wounds Under 200K are Treated with a Skin or Dermal Substitute 7 Source: SmartTRAK Business Intelligence

U.S. WOUND BIOLOGICS MARKET DYNAMICS $25 Billion Annual Cost of Treating Chronic Wounds in U.S. SDS Market (Skin/Dermal Substitutes) growth exceeds overall market growth Amniotic Tissue estimated to exceed 50% of market in 2021 Amniotic Tissue estimated at $1.1 Billion in 2021 16% 10% 31% 2017 SDS Market 47% 32% 2021 SDS Market 51% 6% 7% Amniotic Tissue Dermal Allografts Xenografts Cell Based Bioengineering 8 SmartTRAK Business Intelligence and Company Estimates

EPIFIX VLU MULTICENTER TRIAL VLU: EpiFix vs. Control % Subjects Complete Wound Closure VLU: Apligraf vs. Control % Subjects Complete Wound Closure 100% 100% 90% 90% 80% 70% 60% 60% 71% 80% 70% 60% 57% 50% 40% 30% 20% 10% 17% 7% 35% 19% 35% 44% 50% 40% 30% 20% 10% 9% 5% 29% 19% 37% 24% 40% 0% Week 4 Week 8 Week 12 Week 16 0% Week 4 Week 8 Week 12 Week 24 EpiFix (N=52) Control (N=57) Apligraf (N=130) Control (N=110) The MiMedx Control was More Efficacious than the Apligraf Control Controls: Multi Layer Compression Therapy with EpiFix NuDerm Alginate Apligraf Moist Gauze with Zinc Paste Please note: Apligraf and EpiFix studies are independent of one another Apligraf Reference: PMA Supplement (P950032) approval dated 05/22/1998 EpiFix Reference: Published Final Data Report, Reported Press Release 08/31/2017 9

TARGET HIGH VALUE SURGICAL PROCEDURES Number of Procedures (000) 4.3M Addressable Market Value ($M) $5.7B 1,528 Orthopedics Spine, Trauma, Extremities, Sports Medicine 2,821 1,154 GYN Hysterectomy, Endometriosis, Myomectomy, C Section, Episiotomy $2.9B 1,000 652 714 237 PLASTICS Hand Tendon and Nerves, Mohs, Scar Revision, Skin Grafting, Surgical Site Dehiscence, Burn GENERAL COLORECTAL Bariatric, Fistula Repair, GI Anastomosis UROLOGY Prostatectomy, Partial Nephrectomy, Cystectomy 990 714 200 Source: Millenium Research Group, MRG Lap 2014, ASPS Statistics, MiMedx 2015 Annual Plan, MiMedx internal coding data, Management Estimates 10

MUSCULOSKELETAL PAIN AND DEGENERATION Lead Product Candidate: AmnioFix Injectable Micronized Amniotic Tissue Cellular Proteins Address Multiple Targets with a Unified Mechanism of Action Includes Factors Required for Soft Tissue Homeostasis and Repair 3 BLA Programs Targeting Musculoskeletal Pain Plantar Fasciitis Achilles Tendonitis Osteoarthritic Knee Pain Positive Phase 2B Data from Plantar Fasciitis Study Validates Therapeutic Effect of AI in Treating Soft Tissue Pain, Restoring Function and Improving Quality of Life AI Granted Regenerative Medicine Advanced Therapy (RMAT) designation by FDA for Osteoarthritis Knee Pain Increases Dialogue; May Reduce Time to Gain BLA approval 11

U.S. JOINT PAIN INJECTION OPPORTUNITY 2015 U.S. Joint Pain Injection Market* 12 * SmartTRAK Business Intelligence and Company Estimates Market Opportunity: 80% of total injections are for tendonitis and osteoarthritic pain

PAIN MANAGEMENT CLINICAL PROGRAMS 13 2018 2021: Management s Estimation

PLANTAR FASCIITIS: FINAL PHASE 2B DATA SHOW POSITIVE PAIN AND FOOT FUNCTION RESULTS Clinically Meaningful and Statistically Significant Difference compared to Control Group Primary Efficacy Endpoint: Reduction in VAS (visual analog scale) score for pain (p<0.0001) Secondary Efficacy Endpoint: Improvement in FFI R (Foot Function Index Revised) score (p=0.0004) At 3 month follow up visit, Average Reduction VAS score for Pain was 76% vs. 45% for Control Percent Reduction from Baseline 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Baseline 1 Month 2 Months 3 Months 6 Months AmnioFix At 3 Months, Subjects in the Placebo Group Were Allowed to Undergo Alternative Therapy Saline 14

PLANTAR FASCIITIS PHASE 2B STUDY OUTLINE A Prospective, Single Blinded, Randomized Controlled Trial of Micronized dhacm Injection Compared to Saline Placebo Injection in the Treatment of PF PURPOSE DESIGN PRIMARY SECONDARY To Determine Whether AmnioFix Injectable (mdhacm) is Effective in the Treatment of Recalcitrant Plantar Fasciitis Randomized, Multi Center, Single Blind (Patient) 147 Patients with Recalcitrant PF (Confirmed Diagnosis >1 Month and < 18 Months, VAS > 45, Conservative Usual Care > 1 Month*) 2 Arm Unilateral Treatment with: n=73: Placebo (1 ml Normal Saline) n=74: AmnioFix Injectable (1ml of 40 mg AI) Mean Change in VAS Score from Baseline at 3 Months Incidence of Adverse Events at 12 Months Mean Change in Functional Score by FFI R at 3 Months Immuno Compatibility of First 20 Patients at 3 and 12 Months FFI R and VAS at 6 and 12 Months 15 * Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics

PLANTAR FASCIITIS PHASE 3 STUDY OUTLINE A Prospective, Double Blinded, Randomized Controlled Trial of Micronized dhacm Injection Compared to Saline Placebo Injection in the Treatment of PF PURPOSE DESIGN PRIMARY SECONDARY To Determine Whether AmnioFix Injectable (mdhacm) is Effective in the Treatment of Recalcitrant Plantar Fasciitis Randomized, Multi Center, Double Blinded (Patient and Reviewer) 164 Patients with Recalcitrant PF (Confirmed Diagnosis >1 Month and < 18 Months, VAS > 45, Conservative Usual Care > 1 Month*) 2 Arm Unilateral Treatment with: n=82: Placebo (1 ml Normal Saline) n=82: AmnioFix Injectable (1ml of 40 mg AI) Mean Change in VAS Score from Baseline at 3 Months Incidence of Adverse Events at 6 Months Mean Change in Functional Score by FFI R at 3 Months FFI R and VAS at 6 Months 16 * Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics

ACHILLES TENDONITIS PHASE 3 STUDY OUTLINE A Prospective, Double Blinded, Randomized Controlled Trial of Micronized dhacm Injection Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis PURPOSE DESIGN To Determine Whether AmnioFix Injectable (mdhacm) is Effective in the Treatment of Achilles Tendonitis Randomized, Multi Center, Double Blinded (Patient and Reviewer) 158 patients with Achilles Tendonitis (Confirmed Diagnosis >1 Month and < 18 Months, VAS > 45, Conservative Usual Care > 1 Month*) 2 Arm Unilateral Treatment with: n=79: Placebo (1 ml Normal Saline) n=79: AmnioFix Injectable (1ml of 40 mg AI) PRIMARY SECONDARY Mean Change in VAS Score from Baseline at 3 Months Incidence of Adverse Events at 6 Months Mean Change in Functional Score by FFI R at 3 Months FFI R and VAS at 6 Months 17 * Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics

OA IS A BOOMING EPIDEMIC AND COST BURDEN Osteoarthritis (OA) Affects an Estimated 31M Americans Most Common form of Arthritis Leading Cause of Disability in American Adults Prevalence Increases with Age 80% Incidence in Persons Over 75 14M Americans Suffer Symptomatic Knee OA Over $27B in Annual U.S Health Care Expenditures Annual Medicare Burden Attributed to Total Joint Arthritis Expected to Exceed $50B in 2030* Source: Arthritis Foundation * Wilson NA, Schneller ES, Montgomery K, Bozic KJ. Hip and knee implants: current trends and policy considerations. Health Aff (Millwood) 2008;27:1587 98. doi: 10.1377/hlthaff.27.6.1587 18

AI MEETS REQUIREMENTS FOR A NEW FRONTLINE THERAPY * * * ** * * *** 19 * Toxic side effects and limited efficacy ** Limited efficacy

AI GRANTED RMAT DESIGNATION FOR KNEE OA FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to AmnioFix Injectable to Treat Osteoarthritis (OA) of the knee Promising Therapies in Areas of Considerable Unmet Medical Need RMAT designation includes a comprehensive discussion with FDA on clinical trials and strategy for expediting manufacturing development Designation Facilitate Dev. & Expedite Review (e.g. Rolling) Intensive FDA Guidance on Dev. FDA Senior Mgmt. Involvement Surrogate Endpoints Early Approval RMAT X X X Possible Possible RMAT Treat, Modify, Reverse, or Cure Serious Condition Treat, Modify, Reverse, Cure Address Unmet Need Regenerative Medicine Therapy Preliminary Clinical Data Needed X X X 20

OSTEOARTHRITIS PHASE 2B STUDY OUTLINE A Prospective, Double Blinded, Randomized Controlled Trial of Micronized dhacm Injection Compared to Saline Placebo Injection in the Treatment of Osteoarthritis PURPOSE To Determine Whether AmnioFix Injectable (mdhacm) is Effective in the Treatment of Osteoarthritis DESIGN PRIMARY SECONDARY Randomized, Multi Center, Double Blinded (Patient and Reviewer) 318 Patients with Osteoarthritis (Diagnosis of Osteoarthritis (OA) Defined as Grade 1 to 3 on the Kellgren Lawrence Grading Scale, VAS > 45) 2 Arm Unilateral Treatment with: n=159: Placebo (1 ml Normal Saline) n=159: AmnioFix Injectable (1ml of 40 mg AI) Mean Change in VAS Score Between Baseline and 3 Months Mean Change in WOMAC 3.1 Score (Pain, Stiffness and Physical Function) Incidence of Adverse Events at 12 Months Mean Change in Functional Score as Measured by KOOS at 3 Months Long Term KOOS and VAS at 12 Months 21 * Including any of the following modalities: RICE, Steroid Injection, Stretching, NSAID, Orthotics

KEY 2018 MILESTONES Patient enrollment started in early January for our Pivotal Phase 3 BLA clinical trials for both Plantar Fasciitis and Achilles Tendonitis Favorable settlement of lawsuit upholding validity of patent and IP rights AmnioFix Injectable Granted RMAT Designation by FDA for Osteoarthritis Knee Pain Positive Pain & Foot Function Results from Phase 2B Plantar Fasciitis Trial First Patient Enrolled in Phase 2B Osteoarthritis Knee Pain BLA Trial Reporting DFU Multicenter Data Additional Reimbursement Wins Continued International Expansion 22

SUMMARY HIGHLIGHTS Leading Developer and Marketer of Regenerative and Therapeutic Biologics Proprietary PURION Process Retains a Milieu of 520+ Proteins (Growth Factors, Chemokines and Cytokines) within Placental Tissue Allografts Proven Product Safety Profile; Over 100* Issued and Allowed Patents Addressing Multi Billion Dollar Market Opportunities in Wound Care, Surgical and Musculoskeletal Pain Strong, Core Regenerative Product Portfolio with Pipeline of Therapeutic Biologics for Continued Growth Beyond 2020 *owned and licensed 23